In recent decades there have been remarkable reductions in death from cardiovascular diseases, largely due to a decreased prevalence of smoking and modern science that has led to effective therapies for hypertension and high cholesterol. Even so, cardiovascular diseases (CVD) remain the number one cause of death worldwide.1
Internal Medicine – Metabolic Diseases
CVD continues as an epidemic, driven by a number of factors, including the rising rates of obesity and its resulting metabolic diseases, such as type 2 diabetes mellitus and the metabolic syndrome, which refers to the group of risk factors that increase an individual’s risk for heart disease and other health problems.2 The modern lifestyle has promoted a new array of cardiovascular risk factors, but treatments for these have remained elusive. We believe that a comprehensive program is needed to address the collection of diseases of the cardiovascular system, as well as their root causes, including obesity and metabolic disease.
We now understand obesity leads to diabetes, and diabetes in turn increases the risk of heart failure and other types of heart disease. In fact, more than two-thirds of people age 65 or older with diabetes die from some form of heart disease.3 Another significant area of unmet need that reflects the global dysmetabolic state is non-alcoholic steatohepatitis (NASH). NASH is preceded by an abnormal accumulation of lipid in the liver, a condition that is associated with obesity and insulin resistance and is estimated to impact as many as 30% of all adults in the US.4 Ultimately, NASH can lead to liver fibrosis, cirrhosis and eventually liver failure5 or cancer6, and has no approved treatment.
With costly hospitalizations on the rise, economists project that failure to properly invest in prevention and treatment could cost as much as $47 trillion worldwide by 2036.7
For more than 50 years, Pfizer has led the way in redefining the management of cardiovascular risk by bringing much-needed treatments to patients.
Today, Pfizer is focused on investigating potential therapies that treat both the metabolic abnormalities that increase the likelihood of cardiovascular disease and the heart itself by trying to alter the way it responds to the abnormal metabolic state. This includes more targeted potential therapies, as well as possible therapies that are a combination of two or more drugs, which could bring additional benefits to patients.
Our early discovery efforts focus on emerging areas of CV research such as control of eating disorders, type 2 diabetes/muscle uptake of glucose and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Work with Us
If you’re interested in collaborating with our Metabolic Disease & Cardiovascular Risk research team and want to learn more about our work, visit our Internal Medicine Partnering page. We welcome the opportunity to discuss how we can work together.